Preferred Label : Lapatinib;
MeSH definition : A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR,
ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast
cancer, where tumors overexpress HER2.;
MeSH synonym : N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl)
-2-furyl)-4-quinazolinamine;
MeSH hyponym : GW282974X; GW-282974X; GW-572016; GW 572016;
MeSH Related Number : G873GX646R;
UNII : 0VUA21238F;
Origin ID : D000077341;
UMLS CUI : C1506770;
ATC code(s)
- Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- Validated automatic mappings to BTNT
A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR,
ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast
cancer, where tumors overexpress HER2.
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Inhibiteurs-intracellulaires-des-recepteurs-EGFR-et-HER2-lapatinib-et-tucatinib
2022
France
guidelines for drug use
tucatinib
Lapatinib
receptors, opioid, mu
lapatinib
EGF Receptors
tucatinib
---
https://ansm.sante.fr/informations-de-securite/Lapatinib-Tyverb-Mise-a-jour-importante-du-Resume-des-Caracteristiques-du-Produit
2019
false
false
false
France
French
guidelines for drug use
Lapatinib
breast neoplasms
drug evaluation
antineoplastic combined chemotherapy protocols
neoplasm metastasis
postmenopause
lapatinib
aromatase inhibitors
Hormone receptor positive malignant neoplasm of breast (disorder)
---
http://www.has-sante.fr/portail/jcms/c_1756827/fr/tyverb
2014
false
France
French
guidelines for drug use
Trastuzumab
evaluation of the transparency committee
quinazolines
antineoplastic agents
protein kinase inhibitors
insurance, health, reimbursement
administration, oral
lapatinib
breast neoplasms
neoplasm metastasis
antineoplastic combined chemotherapy protocols
receptor, erbB-2
adult
aged
treatment outcome
antineoplastic agents
quinazolines
protein kinase inhibitors
lapatinib ditosylate
lapatinib ditosylate
HER2 positive breast cancer
Lapatinib
Lapatinib
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/tykerb-2393.html
2013
false
Canada
English
French
evaluation of the transparency committee
Tyrosine Kinase Inhibitors
protein kinase inhibitors
lapatinib
receptor, erbB-2
antineoplastic combined chemotherapy protocols
postmenopause
treatment outcome
Cost-Benefit analysis
clinical trials, phase iii as topic
survival analysis
administration, oral
breast neoplasms
neoplasm metastasis
antineoplastic agents
quinazolines
HER2 positive breast cancer
drug evaluation
ErbB Receptors
Lapatinib
---
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26285a-fra.php
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26287a-fra.php
2013
false
Canada
French
English
Trastuzumab
treatment outcome
lapatinib ditosylate
lapatinib
antineoplastic combined chemotherapy protocols
breast neoplasms
neoplasm metastasis
receptor, erbB-2
antineoplastic agents
clinical trials, phase iii as topic
disease-free survival
pharmacovigilance note
Lapatinib 250mg tablet (product)
administration, oral
protein kinase inhibitors
quinazolines
HER2 positive breast cancer
comparative study
Lapatinib
---
https://www.ema.europa.eu/medicines/human/EPAR/Tyverb
2012
false
United Kingdom
English
French
syndication feed
Capecitabine
Anastrozole/Lapatinib Regimen
HER2-positive hormone receptor positive metastatic breast cancer in postmenopausal
women
Exemestane/Lapatinib Regimen
Lapatinib/Letrozole Regimen
Capecitabine/Lapatinib Regimen
breast cancer whose tumours overexpress HER2 with hormone receptor-negative metastatic
disease that has progressed
Lapatinib/Trastuzumab Regimen
protein kinase inhibitors
antineoplastic agents
breast neoplasms
quinazolines
neoplasm metastasis
antineoplastic combined chemotherapy protocols
tablets
administration, oral
drug approval
drug evaluation, preclinical
treatment outcome
drug labeling
antineoplastic agents
protein kinase inhibitors
receptor, erbB-2
antimetabolites, antineoplastic
drug interactions
pregnancy
breast feeding
food-drug interactions
quinazolines
lapatinib
lapatinib ditosylate
lapatinib ditosylate
summary of product characteristics
drug evaluation
package leaflet
Lapatinib
Lapatinib
---
http://www.meddispar.fr/Medicaments/TYVERB-250-FL-140/%28type%29/letter/%28value%29/T/%28cip%29/3400941701825
2011
false
France
French
lapatinib ditosylate
administration, oral
legislation, drug
drug prescriptions
lapatinib
antineoplastic agents
continuity of patient care
quinazolines
drug information
Lapatinib
---
http://www.has-sante.fr/portail/jcms/c_1001258/tyverb
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/tyverb_-_ct-8653.pdf
2010
false
France
French
evaluation of the transparency committee
quinazolines
antineoplastic agents
protein kinase inhibitors
insurance, health, reimbursement
administration, oral
lapatinib
breast neoplasms
neoplasm metastasis
antineoplastic combined chemotherapy protocols
receptor, erbB-2
adult
aged
treatment outcome
antineoplastic agents
quinazolines
protein kinase inhibitors
lapatinib ditosylate
lapatinib ditosylate
HER2 positive breast cancer
Lapatinib
Lapatinib
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00156
2009
false
Canada
French
breast neoplasms
antineoplastic agents
HER2 positive breast cancer
Lapatinib 250mg tablet (product)
lapatinib ditosylate
lapatinib
administration, oral
neoplasm metastasis
drug evaluation
Lapatinib
quinazolines
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=65609052
2008
false
France
French
quinazolines
administration, oral
tablets
lapatinib ditosylate
lapatinib
drug information
Lapatinib
---
http://www.has-sante.fr/portail/jcms/c_684109/tyverb
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-09/tyverb_ct_5358.pdf
2008
false
France
French
English
guidelines for drug use
antineoplastic agents
protein kinase inhibitors
breast neoplasms
quinazolines
neoplasm metastasis
receptor, erbB-2
tablets
administration, oral
antineoplastic combined chemotherapy protocols
treatment outcome
survival analysis
insurance, health, reimbursement
lapatinib ditosylate
lapatinib
evaluation of the transparency committee
HER2 positive breast cancer
Lapatinib
---
